Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Almirall

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Almirall's 2013 sales performance.

Forest and Almirall delay FDA filing of COPD drug

Forest and Almirall delay FDA filing of COPD drug Both Forest and Almirall are now working with the FDA regarding these specifications, although gave no potential date for future submission. ... The delay is a blow to Forest and Almirall's plans in the field and could let their rivals steal a march.

Almirall launches Sativex in Italy

Almirall launches Sativex in Italy Brings cannabis-based drug for multiple sclerosis spasticity to market. Almirall has launched its cannabinoid treatment Sativex for moderate to severe spasticity in multiple sclerosis (MS) patients in Italy.

New chief information officer at Bayer Healthcare

New chief information officer at Bayer Healthcare He succeeds Matthias Moritz, who left Bayer in March 2013 to join Almirall.

GSK submits COPD drug in US and EU

GSK submits COPD drug in US and EU Other COPD products coming through development include Boehringer Ingelheim's olodaterol, which has also received backing from an FDA panel, Novartis' QVA149 (glycopyrronium bromide and indacaterol maleate) and Forest

GSK buoyed by FDA panel backing for Advair successor

GSK buoyed by FDA panel backing for Advair successor Other COPD combinations coming through development include Boehringer Ingelheim/Pfizer's olodaterol/tiotropium, Novartis' QVA149 (glycopyrronium bromide and indacaterol maleate) and Forest Labs/Almirall's aclidinium bromide/formoterol candidate,

[ Previous 5 results ] 6 7 8 9 10 11 12 13 14 15 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....

Infographics